• UCLA Health
  • myUCLAhealth
  • School of Medicine
UCLA Health

UCLA Health
  • About Us
    • What is UCLA Health?
    • Contact Us
    • Your Feedback
    • Accountable Care Organization
    • Awards & Achievements
    • Careers
    • Careers for Physicians
    • Departments - Administrative
    • Departments - Clinical
    • Giving to UCLA Health
    • Health Equity, Diversity & Inclusion
    • In the Community
    • Industry Relations
    • Innovation
    • Leadership
    • News Releases
    • Price Transparency
    • Social Media
    • #TeamLA
    • 340B Program
    Vital SignsLinked Graphic: Subscribe to Health Newsletters
    • Contact
    • Your Feedback
    • Accountable Care Organization
    • Awards and Achievements
    • Careers
    • Careers for Physicians
    • Departments - Administrative
    • Departments - Clinical
    • Giving to UCLA Health
    • Health Equity, Diversity and Inclusion
    • Industry Relations
    • Innovation
    • In the Community
    • 340B Program
    • Leadership
    • News Releases
    • Price Transparency
    • Social Media
    • TeamLA
    • Subscribe to UCLA Health Newsletters
  • Conditions & Treatment
    • Health Library
    • Tests & Procedures
    • Drug Interaction Checker
    • Brain & Nervous System
    • Cancer
    • Children's Health
    • Heart Disease
    • Nutrition & Wellness
    • Pregnancy & Newborns
    • Orthopedics
    • Women's Health
    • Video Library
    • Cancer
    • Cardiovascular
    • Chiropractic
    • Cosmetic Surgery
    • Ear, Nose and Throat
    • Gastrointestinal
    • General Healthcare
    • Neurological
    • Obstetrics/Gynecology
    • See all videos...
    Symptom Checker
    • Video Library
  • Locations

    Hospitals

    • Ronald Reagan UCLA Medical Center
    • UCLA Santa Monica Medical Center
    • UCLA Mattel Children's Hospital
    • Resnick Neuropsychiatric Hospital
    • Institutes and Centers
    • Take a Virtual Tour

    Medical Offices/Clinics

    • Primary Care
    • Specialty Care
    • Immediate Care
    • Emergency Care
    • Outpatient Surgery Centers
    • Community Cancer Care
    • Pediatric Locations
    • Imaging/Radiology
    • Clinical Labs
    • Pharmacies

    Interactive Map

    interactive map

    • Interactive Map
    • UCLA Medical Plazas
    • Locations Coming Soon
    • UCLA Hospitals
    • Take a Virtual Tour
    • Primary Care Practices
    • Specialty Care Practices
    • Immediate Care
    • Emergency Care
    • Pediatric Locations
    • Outpatient Surgery Centers
    • Clinical Labs
    • Pharmacies
    • Other Locations
    • Interactive Map
    • Coming Soon!
  • Medical Services
  • For Patients & Visitors
    • Directions & Parking
    • Appointments
    • Video Visits
    • Medical Chaperones
    • Admissions
    • Preparing For Surgery
    • Patient Services
    • Security & Parking Services
    • Office of the Patient Experience
    • For International Patients
    • Lodging & Nearby Services
    • Around Westwood
    • Gift Shops & Flowers
    • Patient Greeting Cards
    • Coronavirus Resources
    • Log in to myUCLAhealth
    • Billing and Insurance
    • Medical Records
    • Price Transparency
    • Health Encyclopedia
    • Interactive Patient Education Videos (Emmi)
    • FAQs
    • Calendar of Events
    • Secure Email Messages
    • Health Resources
    • Multimedia
    • Download our Apps
    • Doctor on video visit
    • Open Enrollment
    • Visit our Connect Blog
    • Send a Care Compliment
    • Read Health Publications
    • Vital Signs Newsletters
    • Join a Patient and Family Advisory Council
    • Share your Feedback
    • Contact Us
    • Appointments: Call, Click, Come in
    • Video Visits - Telemedicine
    • Medical Chaperones
    • Admissions Information
    • Advance Directive
    • Directions & Parking
    • Patient Services
    • Medical Records
    • myUCLAhealth
    • Smoke-Free
    • Publications
    • Multimedia
    • Health Resources
    • Around Westwood
    • Lodging
    • Preparing For Surgery
    • Patient-focused Technology Council
    • Health Forms
    • End of Life Option Act: Resources & Materials
    • Frequently Asked Questions
    • Secure Email Messages
    • Gift Shops
    • Patient Greeting Cards
  • For Healthcare Professionals
    • Referring a Patient
    • Continuing Medical Education
    • Ethics Center
    • UCLA HealthLink
    • Physician to Physician Access Line (P2P)
    • David Geffen School of Medicine at UCLA
    • Clinical Informatics Fellowship
    • Academic Positions
    • Physician Careers
    • UCLA School of Dentistry
    • UCLA School of Nursing
    • Department of Nursing

    Physician Publications

    • Physicians Update
    • Clinical Updates
    • U Magazine
    • Physician to Physician Access Line (P2P)
    • Physician Careers
    • Clinical Informatics Fellowship
    • Flu Resources for Healthcare Professionals
    • Publications
  • Clinical Research
    • All Clinical Trials
    • COVID-19 Clinical Research
  • Find a Provider
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

News Releases

  1. Home
  2. About Us
  3. News Releases

News Releases

Health and Behavior

Virus-mimicking drug helps immune system target cunning cancer cells

10/14/2020
Kalbasi, Ribas

Dr. Anusha Kalbasi (left) and Dr. Antoni Ribas

Researchers at the UCLA Jonsson Comprehensive Cancer Center have found that a drug that activates the body's natural defenses by behaving like a virus may also make certain stealthy melanoma tumors visible to the immune system, allowing them to be better targeted by immunotherapy.

The findings, published today in the journal Science Translational Medicine, open up the possibility of using drugs that mimic viruses to overcome immunotherapy resistance in tumors with defective interferon signaling and help create more personalized therapies for people with hard-to-treat cancers.

"Most immunotherapy approaches rely on the ability of T cells to recognize and kill tumor cells," said lead and corresponding author Dr. Anusha Kalbasi, an assistant professor of radiation oncology at the David Geffen School of Medicine at UCLA and member of the Jonsson Cancer Center. "But in some patients, tumors escape the immune system through mutations in genes involved in the interferon signaling pathway. This is a critical pathway because it normally allows tumors to increase their antigen presentation, an intricate machinery that makes tumors visible to T cells."

Interferons are proteins in cells that respond to viral infection by impeding the virus’s ability to replicate and alerting the immune system to marshal its forces. Activating interferon signaling in tumors helps slow down tumor division and can lead to the release of molecules that recruit more immune cells to the tumor.

"This coordinated effort as a result of interferon signaling can help the immune system better identify and kill tumor cells," Kalbasi said.

The team first attempted to overcome defective interferon signaling by using adoptive T cell therapy, a type of immunotherapy that involves extracting T cells from a patient and engineering them in the laboratory to recognize and kill cancer cells. The researchers found that these T cells remained ineffective against tumors with defective interferon signaling.

The authors then engineered mouse melanoma tumor cells with a gene called NLRC5. NLRC5 increased antigen presentation even in the absence of interferon signaling and restored the effectiveness of the T cells. While this approach was effective in mice, engineering tumor cells in humans was not as simple.

Instead, Kalbasi and his colleagues turned to a virus-mimicking drug called BO-112 that activates virus-sensing pathways in tumors. When the drug was injected directly into the tumor in the laboratory, the team discovered that the activation of virus-sensing pathways increased antigen presentation even when interferon signaling was defective. As a result, these tumors could be recognized and killed by T cells.

"This study helps us understand the interdependence between interferon signaling and antigen presentation, which gives us important insights into how tumor cells are recognized by the immune system," said the study's senior author, Dr. Antoni Ribas, a professor of medicine at the Geffen School of Medicine and director of the tumor immunology program at the Jonsson Cancer Center. "New strategies to promote antigen presentation to make tumors more visible to the immune system will allow immunotherapy to be effective for even more tumor types."

The findings also highlight the potential of other promising clinical approaches that bypass tumor interferon signaling and antigen presentation, like CAR, or chimeric antigen receptor–based T cell therapy, which can recognize and kill tumor cells even in absence of antigen presentation.

Kalbasi is now leading a human clinical trial of the combination therapy of nivolumab, an immune checkpoint blockade drug, and BO-112 in people with certain types of sarcoma who are undergoing radiation followed by surgery. The idea is to activate the immune system against the patient's tumor while the tumor is still in the body.

The research is a collaboration with colleagues at Highlight Therapeutics, a biotechnology company based in Spain that has developed and tested BO-112 in early-phase clinical trials in Europe. The work was supported in part by the Parker Institute for Cancer Immunotherapy and the National Institutes of Health.

Other UCLA authors include: Mito Tariveranmoshabad, Kevin Hakimi, Sarah Kremer, Katie Campbell, Juan Funes, Agustin Vega-Crespo, Giulia Parisi, Ameya Champekar, Christine Nguyen, Davis Torrejon, Daniel Shin, Jesse Zaretsky and Robert Damoiseaux.



Media Contact
Denise Heady
(310) 206-2805
DHeady@mednet.ucla.edu



Latest News

Health and Behavior
UCLA shares COVID-19 vaccine information with faculty and staff
01/15/2021
Members of the COVID-19 Response and Recovery Task Force updated faculty and staff on the progress of UCLA Health's vaccination program and to take questions.

Health and Behavior
In lab study, nanoparticle shows promising results for treating severe allergies
01/14/2021
A UCLA research team developed a possible way to impart long-term relief by inducing an active state of immune tolerance.

Health and Behavior
Cancer researchers awarded grant to study genomic alterations in prostate cancer
01/12/2021
Paul Boutros, PhD, Robert Reiter, MD, and Huihui Ye, MD, MS, of the UCLA Jonsson Comprehensive Cancer Center have received the 2020 Prostate Cancer Foundation Special Challenge Award to help improve the understanding of prostate cancer biology and identify new ways to help prevent, diagnose, prognose and treat lethal prostate cancer.

Health and Behavior
UCLA scientists develop method to more efficiently isolate and identify rare T cells
01/11/2021
Scientists from the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have developed a technique that will enable researchers to more efficiently isolate and identify rare T cells that are capable of targeting viruses, cancer and other diseases.

Health and Behavior
MRI frequently underestimates tumor size in prostate cancer
01/07/2021
Research brief: Improving imaging processes will lead to more successful treatments and help reduce morbidity in men with the disease.

Facebook Twitter Instagram Youtube LinkedInWeibo
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap

Sign in to myUCLAhealth

Learn more about myUCLAhealth